Ironwood Pharmaceuticals Inc (IRWD)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas A. McCourt
Employees:
220
301 BINNEY STREET, CAMBRIDGE, MA 02142
617-621-7722

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation.

Data derived from most recent annual or quarterly report
Market Cap 1.529 Billion Shares Outstanding159.22 Million Avg 30-day Volume 2.066 Million
P/E Ratio12.3144 Dividend Yield0.0 EPS0.33
Price to Revenue5.1286 Debt to Equity0.0 EBITDA249.581 Million
Price to Book Value0.0 Operating Margin56.6032 Enterprise Value0
Current Ratio0 EPS Growth-0.685 Quick Ratio0
1 Yr BETA 0.6786 52-week High/Low 12.66 / 8.08 Profit Margin41.6469
Operating Cash Flow Growth16.5848 Free Cash Flow to Firm (FCFF) TTM 647.713 Million Free Cash Flow to Equity (FCFE) TTM308.721 Million
Altman Z-Score0.0
Earnings Report2024-02-22
View SEC Filings from IRWD instead.

View recent insider trading info

Ironwood Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding IRWD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IRWD

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-11-22 by DAVIS ANDREW
  • 4: filed on 2023-11-20 by EMANY SRAVAN KUMAR
  • 4: filed on 2023-09-19 by MOUKHEIBIR CATHERINE
  • 4: filed on 2023-09-18 by EMANY SRAVAN KUMAR
  • 4: filed on 2023-08-31 by SILVER RONALD
  • 4: filed on 2023-08-16 by SILVER RONALD
  • 4: filed on 2023-08-16 by JOHN MINARDO
  • 4: filed on 2023-06-22 by SHEPARD JAY
  • 4: filed on 2023-06-22 by MOUKHEIBIR CATHERINE
  • 4: filed on 2023-06-22 by MCHUGH JULIE

    • Events (8k)

  • 8-K: filed on 2023-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2023-09-11:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-30:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-11:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-19:
  • 144: filed on 2023-05-19:
  • 144: filed on 2023-05-19:
  • 144: filed on 2023-05-08:
  • 144: filed on 2023-05-30:
  • 144: filed on 2023-06-07:
  • 144: filed on 2023-08-01:
  • 144: filed on 2023-08-11:
  • 144: filed on 2023-11-17:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    3.3 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DAVIS ANDREW SVP, CHIEF BUSINESS OFFICER

    • Officer
    		 217,374 2023-11-20 4

    EMANY SRAVAN KUMAR SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 182,069 2023-11-16 3

    DENNER ALEXANDER J

    SARISSA CAPITAL MANAGEMENT LP

    • Director
    • 10% Owner
    		 16,508,930 2023-09-15 5

    MOUKHEIBIR CATHERINE

    • Director
    		 127,061 2023-09-15 4

    SILVER RONALD PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 142,172 2023-08-29 4

    JOHN MINARDO CHIEF LEGAL OFFICER

    • Officer
    		 192,195 2023-08-14 3

    CURRIE MARK G

    • Director
    		 544,108 2023-06-20 1

    MCHUGH JULIE

    • Director
    		 162,294 2023-06-20 1

    SHEPARD JAY

    • Director
    		 102,244 2023-06-20 1

    DREYFUS ANDREW

    • Director
    		 168,980 2023-06-20 1

    KESSLER MARLA L

    • Director
    		 106,498 2023-06-20 1

    DUANE JON R

    • Director
    		 114,108 2023-06-20 1

    MCCOURT THOMAS A CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 758,284 2023-05-30 9

    SHETZLINE MICHAEL CMO,SVP,HEAD-RES&DRUG

    • Officer
    		 321,131 2023-05-22 4

    RICKARD JASON SVP, CHIEF OPERATING OFFICER

    • Officer
    		 376,316 2023-03-08 4

    OLANOFF LAWRENCE S

    • Director
    		 91,395 2021-06-02 0

    OWENS EDWARD P

    • Director
    		 281,720 2021-06-02 0

    CONSYLMAN GINA SVP, CFO & TREASURER

    • Officer
    		 392,616 2021-03-26 0

    DENNER ALEXANDER J

    • Director
    		 29,972,944 2021-02-26 5

    MALLON MARK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 470,605 2021-02-26 0

    KILROY CONOR SVP, GC & SECRETARY

    • Officer
    		 No longer subject to file 2021-02-26 0

    MACDONALD KELLY CHIEF ACCOUNTING OFFICER

    • Officer
    		 93,041 2020-12-04 0

    GILBERT HALLEY E CHIEF ADMIN OFFICER & SVP

    • Officer
    		 265,991 2020-02-21 0

    MCGUIRE TERRANCE

    • Director
    		 No longer subject to file 2019-04-01 0

    WILLIAMS DOUGLAS E

    • Director
    		 No longer subject to file 2019-04-01 0

    FANUCCI MARSHA

    • Director
    		 No longer subject to file 2019-04-01 0

    SCHULMAN AMY W

    • Director
    		 No longer subject to file 2019-04-01 0

    HECHT PETER M CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 No longer subject to file 2019-04-01 0

    HUYETT WILLIAM CHIEF OPERATING OFFICER

    • Officer
    		 No longer subject to file 2019-04-01 0

    WALSH CHRISTOPHER T PHD

    • Director
    		 374,525 2017-03-15 0

    GRANEY THOMAS CHIEF FINANCIAL OFFICER

    • Officer
    		 42,013 2017-02-27 0

    ROBERTS BRYAN E

    • Director
    		 123,978 2015-06-15 0

    CONRADES GEORGE H

    • Director
    		 635,976 2015-06-03 0

    EBERSMAN DAVID A

    • Director
    		 101,233 2015-03-13 0

    COOK JOSEPH C JR

    • Director
    		 328,080 2015-03-11 0

    HIGGINS MICHAEL J CHIEF OPERATING OFFICER

    • Officer
    		 329,102 2014-12-23 0

    SHAW DAVID EVANS

    • Director
    		 393,455 2014-03-14 0

    FMR LLC

    FIL LTD

    • 10% Owner
    • EDWARD C. JOHNSON 3DEDWARD C. JOHNSON 3D
    		 837,736 2013-03-28 0

    VENROCK ASSOCIATES

    VENROCK ASSOCIATES II LP

    VENROCK ENTERPRENEURS FUND LP

    VR MANAGEMENT LLC

    • 10% Owner
    		 No longer subject to file 2013-03-15 0

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP MANAGEMENT, LLC

    VENROCK ASSOCIATES V LP

    VENROCK PARTNERS V L P

    VENROCK MANAGEMENT V, LLC

    VENROCK PARTNERS MANAGEMENT V, LLC

    HOVE ANDERS D

    • 10% Owner
    		 No longer subject to file 2013-03-15 0

    FMR LLC

    • 10% Owner
    • EDWARD C. JOHNSON 3D
    		 2,340,891 2012-07-09 0

    RIDGEBACK CAPITAL INVESTMENTS L.P.

    RIDGEBACK CAPITAL INVESTMENTS LTD.

    RIDGEBACK CAPITAL MANAGEMENT LP

    • 10% Owner
    		 No longer subject to file 2012-02-02 0

    VR MANAGEMENT LLC

    • 10% Owner
    		 42,667 2011-03-31 0

    VENROCK ASSOCIATES

    VENROCK ASSOCIATES II LP

    VENROCK ENTERPRENEURS FUND LP

    VENROCK MANAGEMENT LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    VR MANAGEMENT LLC

    HOVE ANDERS D

    • 10% Owner
    		 8,731,321 2010-02-02 0

    MILLER GINA BORNINO

    • Director
    		 770,952 2010-02-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DAVIS ANDREW - Officer SVP, CHIEF BUSINESS OFFICER

    		2023-11-22 16:05:22 -0500 2023-11-20 S 3,287 $9.69 d 217,374 direct -0.1041 0.0 1 -0.1041 2

    EMANY SRAVAN KUMAR - Officer SVP, CHIEF FINANCIAL OFFICER

    		2023-11-20 16:05:22 -0500 2023-11-16 F 6,661 $9.44 d 182,069 direct 1.2807 1.2807 2 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 22:15:04 UTC 4.9031 0.4169 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 21:45:03 UTC 4.9031 0.4169 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 21:15:04 UTC 4.9031 0.4169 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 20:45:04 UTC 4.9031 0.4169 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 20:15:04 UTC 4.9031 0.4169 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 19:45:03 UTC 4.9031 0.4169 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 19:15:04 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 18:45:03 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 18:15:03 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 17:45:04 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 17:15:04 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 16:45:04 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 16:15:04 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 15:45:03 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 15:15:03 UTC 4.903 0.417 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 14:45:04 UTC 4.9014 0.4186 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 14:15:04 UTC 4.9014 0.4186 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 13:45:04 UTC 4.9014 0.4186 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 13:15:03 UTC 4.9014 0.4186 5200000
    IRONWOOD PHARMACEUTICALS INC IRWD 2023-11-28 12:45:04 UTC 4.9014 0.4186 5200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund IRWD -13.0 shares, $-131.17 2020-03-31 N-PORT
    FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND IRWD -211201.0 shares, $-2247178.64 2023-06-30 N-PORT
    Calamos Investment Trust/IL- Calamos Market Neutral Income Fund IRWD -747630.0 shares, $-8291216.7 2023-07-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments